Study to Evaluate the Safety and Efficacy of CJ-30061 in Hypertensive Patients With Hyperlipidemia

Inclusion Criteria:

• Aged between 19 and 74 years

• Diagnosed with essintial hypertension(average siSBP ≥ 140mmHg) accompanyinghyperlipidemia(LDL-C ≥ 100mg/dL) and were on or off treatment at Visit 1(screening)

• Decided to participate in the study and provided signed informed consent formvoluntarily after receiving explanation of the objectives, methods, and effects of thestudy

Exclusion Criteria:

• Severe hypertension defined as average siDBP ≥ 120mmHg or average siSBP ≥ 200mmHg atVisit 1(screening)

• The difference in BPs between those measured at the reference arm at Visit 1(screening) was ≥ 10mmHg for siDBP or ≥ 20mmHg for siSBP

• LDL-C > 250mg/dL or TG ≥ 400mg/dL at Visit 1(screening)

• Secondary hypertension

• Diagnosis of type 1 diabetes mellitus(DM) or uncontrolled DM(patients on insulintherapy or patients with HbA1c ≥ 9%)